EUVIMEDEUVIMED entdecken
Open Access

KMT2A is a prerequisite of malignant transformation during IDH-mutant gliomagenesis

Marilin S Koch iD, Minh Deo, Claudia Schmidt, Adrianna Podolak, Julian Taranda iD, Michael S Hoetker, Șevin Turcan iD

Neuro-Oncology · 2026

DOI: 10.1093/neuonc/noag006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2026. Verfasst von Marilin S Koch und 6 weiteren Autor:innen. Beteiligte Einrichtung: Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany. Hauptthemen laut MEDLINE: Isocitrate Dehydrogenase, Histone-Lysine N-Methyltransferase, Cell Transformation, Neoplastic, Glioma. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Else Kröner Fresenius Foundation, Heidelberg Research College for Neurooncology, German Cancer Aid, Max-Eder Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

IDH1R132H is the defining mutation of low-grade gliomas (LGGs), inflicting broad epigenetic rewiring that leads to malignant transformation. Recent studies demonstrated that cell fate change from astrocyte to LGG is accompanied by redistribution of H3K4 methylation. By modulating H3K4-methyltransferase KMT2A in a conditionally IDH1R132H-expressing human astrocyte model system, we sought to define requirements of IDH1R132H dependent gliomagenesis and identify novel therapeutic targets.

Methods

Using KMT2A inhibitor MM-102, we targeted H3K4me3 in IDH1R132H -expressing astrocytes, profiling L1CAM expression, proliferation, clonogenicity, invasion and migration, transcriptional and translational changes. Findings were validated in patient-derived IDH1R132H glioma lines with shRNA-mediated knockdown. Epigenetic transformation was characterized with CUT&Tag and MethylationEPIC. Downstream targets were assessed utilizing siRNAs.

Results

KMT2A inhibition significantly decreased L1CAM expression and led to broad transcriptional downregulation, including LGG marker genes. Analyses of transcriptomics and proteomics pointed to altered lipid metabolism and migratory capacity. Phenotypic characterization showed impaired invasion, migration and proliferation. We observed significantly reduced deposition of H3K4me3 at promoters of DEGs and enhanced global DNA methylation. We identified SCD as putative KMT2A-dependent effector whose knockdown reduced clonogenicity. In patient-derived models, KMT2A suppression impaired viability and spheroid growth in vitro; however, in an orthotopic TS603 model, knockdown shortened survival, indicating stage- and context-dependent effects.

Conclusions

Disrupting KMT2A-mediated H3K4me3 reshapes the epigenome and attenuates LGG-relevant programs and phenotypes in vitro, supporting a strong role in tumor initiation. In vivo, the TS603 survival result highlights context-dependent maintenance and motivates cautious, microenvironment-aware therapeutic exploration of the KMT2A axis and downstream targets such as SCD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Isocitrate DehydrogenaseHistone-Lysine N-MethyltransferaseCell Transformation, NeoplasticGliomaMyeloid-Lymphoid Leukemia ProteinMutationBrain NeoplasmsHumansAnimalsCell ProliferationMiceCell MovementHistonesGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

H3K4me3KMT2Aepigeneticsgliomagenesislow-grade glioma

Substanzen

Isocitrate DehydrogenaseHistone-Lysine N-MethyltransferaseMyeloid-Lymphoid Leukemia ProteinKMT2A protein, humanIDH1 protein, humanHistones

Autor:innen und Institutionen

  • Neurology Clinic and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
  • Clinical Cooperation Unit Neurooncology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Core Facility Unit Light Microscopy, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Department of Internal Medicine V, Hematology, Oncology, and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.

ORCID-Profile: Marilin S Koch, Julian Taranda, Șevin Turcan

Förderung

  • Else Kröner Fresenius Foundation
  • Heidelberg Research College for Neurooncology
  • German Cancer Aid, Max-Eder Program
  • DFG

Zitieren

APA

Koch, M. S., Deo, M., Schmidt, C., Podolak, A., Taranda, J., Hoetker, M. S., & Turcan, Ș. (2026). KMT2A is a prerequisite of malignant transformation during IDH-mutant gliomagenesis. Neuro-Oncology. https://doi.org/10.1093/neuonc/noag006

Vancouver

Koch MS, Deo M, Schmidt C, Podolak A, Taranda J, Hoetker MS, et al. KMT2A is a prerequisite of malignant transformation during IDH-mutant gliomagenesis. Neuro-Oncology. 2026. doi:10.1093/neuonc/noag006

BibTeX
@article{Koch2026,
  author = {Koch, Marilin S and Deo, Minh and Schmidt, Claudia and Podolak, Adrianna and Taranda, Julian and Hoetker, Michael S and Turcan, Șevin},
  title = {KMT2A is a prerequisite of malignant transformation during IDH-mutant gliomagenesis},
  journal = {Neuro-Oncology},
  year = {2026},
  doi = {10.1093/neuonc/noag006}
}
Kostenlos starten →